Finanzen von CRISPR Therapeutics AG (CRSP)CRSPCRISPR Therapeutics AG

Evaluating the bottom line, CRISPR Therapeutics AG maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1127.55%, while the net margin is -895.33%. These profitability ratios, combined with a Return on Equity (ROE) of -26.09%, provide a clear picture of how effectively CRSP converts its operational activities into shareholder value.

In the context of the broader market, CRSP competes directly with industry leaders such as TLX and DNTH. With a market capitalization of $5.50B, it holds a significant position in the sector. When comparing efficiency, CRSP's gross margin of 100.00% stands against TLX's N/A and DNTH's 100.00%. Such benchmarking helps identify whether CRISPR Therapeutics AG is trading at a premium or discount relative to its financial performance.

CRISPR reported a staggering 1,043% revenue growth in Q2, with revenues reaching $10.2 million, up from $892,000 a year ago. Despite ongoing net losses, the gross margin remains strong at 100%.